CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced the formation of a Strategic & Scientific Advisory Board (SSAB) with three key appointments: Louis Kunkel, PhD, Beverly Davidson, PhD, and Jeffrey Chamberlain, PhD.
Help employers find you! Check out all the jobs and post your resume.
